Eli Lilly's rating gets an upgrade to Aa3 by Moody's Ratings
The upgrade is based on Moody's expectation of robust earnings growth for Eli Lilly in the coming years. This growth is anticipated to be driven by the company's incretin portfolio, which includes ...
STAT15h
Lilly expands GLP-1 research to hypertension, neuro conditions
Today, we have a look at the White House's reported plans to make major cuts across federal health agencies. Also, Eli Lilly is expanding the ...
PMLiVE17h
International Alzheimer’s disease prevention trial in at-risk young adults begins
An international clinical trial aimed at preventing Alzheimer’s disease (AD) in young adults who are at risk of developing ...
Malaysian Reserve18h
Most patients on Lilly’s Omvoh® (mirikizumab-mrkz) for Crohn’s disease achieved sustained clinical remission and endoscopic response at two years
More than 90% of Omvoh-treated patients who were in clinical remission at one year sustained it with two years of continuous treatment Nearly 90% of ...
sciencex20h
International Alzheimer's prevention trial in young adults begins
Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...